Physician profile
Michael C Susco
NPI 1285609131
$71,141.85
in general payments reported to CMS, 2019-2025
31 companies · $6,637 in 2025
The $6,637 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,540 · 2020: $3,483 · 2021: $13K · 2022: $17K · 2023: $22K · 2024: $6,521 · 2025: $6,637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $8,302 · Travel and Lodging: $2,490 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,366.00 |
| Food and Beverage | $8,302.00 |
| Travel and Lodging | $2,490.26 |
| Education | $116.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $35,125.48 | 2021-2025 | Vraylar, Mavyret |
| Teva Pharmaceuticals USA, INC. | $19,799.30 | 2020-2025 | Austedo, Uzedy, Austedo Xr |
| Allergan, INC. | $4,181.50 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $1,986.77 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $1,607.28 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,287.80 | 2020-2025 | Caplyta |
| Lundbeck LLC | $938.36 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $811.98 | 2019-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $651.07 | 2021-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $605.06 | 2023-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $588.19 | 2019-2022 | |
| Braeburn INC. | $528.91 | 2023-2025 | Brixadi |
| Janssen Pharmaceuticals, INC | $528.05 | 2019-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $438.81 | 2019-2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $414.42 | 2022-2025 | Fanapt, Hetlioz |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $353.39 | 2024 | Rejoyn |
| Neuronetics, INC. | $226.20 | 2019-2020 | |
| Orexo US, INC. | $221.23 | 2021-2024 | Zubsolv |
| E.R. Squibb & Sons, L.L.C. | $191.76 | 2024-2025 | Cobenfy |
| Shire North American Group INC | $142.93 | 2019 | |
| Corium, LLC | $118.28 | 2022-2025 | Azstarys |
| Almatica Pharma LLC | $113.34 | 2021-2025 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $63.63 | 2023-2024 | Quviviq |
| Eisai INC. | $50.26 | 2020 | |
| Neos Therapeutics, LP | $37.60 | 2019 | |
| Tris Pharma INC | $33.88 | 2022 | |
| Indivior INC. | $25.45 | 2024 | Sublocade |
| Collegium Pharmaceutical, INC. | $23.22 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $17.39 | 2021 | |
| Noven Therapeutics, LLC | $16.68 | 2024 | Secuado, Xelstrym |
| Bausch Health US, LLC | $13.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Susco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.